Description: Biovica International AB (publ), a biotech company, develops and commercializes novel blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in the United States of America. It primarily focuses on breast cancer. The company develops DiviTum TKa, a blood-based biomarker assay that measures thymidine kinase activity, which is correlated with cell proliferation. It serves cancer institutes, pharmaceutical companies, and collaborative groups. Biovica International AB (publ) was incorporated in 2008 and is headquartered in Uppsala, Sweden.
Home Page: www.biovica.com
Dag HammarskjOelds vAeg 54B
Uppsala,
752 37
Sweden
Phone:
46 1 84 44 48 30
Officers
| Name | Title |
|---|---|
| Mr. Anders Rylander | President, CEO & Director |
| Mr. Anders Moren | Chief Financial Officer |
| Ms. Hanna Ritzén | Chief Operating Officer |
| Ms. Helle Fisker | Vice President of Commercial & Marketing |
| Mr. Henrik Winther D.V.M., Ph.D. | Senior Vice President of Business Development |
| Mr. Hector Tamburini | Head of US Laboratory Operations, Regulatory & Quality |
Exchange: ST
Country: SE : Sweden
Currency: Swedish krone (kr)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 13.6986 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.0046 |
| Price-to-Sales TTM: | 37.0597 |
| IPO Date: | |
| Fiscal Year End: | April |
| Full Time Employees: | 27 |